



University of California  
San Francisco

# Prior Authorizations and Coverage

Presented by:

*Rose Pavlakos PharmD, BCACP*  
*Program Pharmacist*

*and*

*Kristine Ramos CPhT*  
*Pharmacy Technician*

# Prior Authorizations (PA)

## Platforms:

### ⑩ CenterXPayor

University of California  
San Francisco

- Does not work for Medicare Part D

- Available through Epic

### ⑩ Covermymeds

- All insurance

- Auto reminder

- Renewal

## Coverage issues or high copays:

- ⑩ Tier exception

- ⑩ Copay cards

- ⑩ 340B program

- ⑩ Medicare Part D Open Enrollment

- ⑩ Patient assistance programs

- Rxassist.org

# PCSK-9 (Praluent and Repatha) and Omega 3 (Vascepa)

## Indication:

- ⑩ PCSK-9: homozygous and heterozygous familial hypercholesteremia, primary hyperlipidemia with ASCVD as adjunct to max tolerated statin, secondary prophylaxis to prevent stroke, MI, coronary revascularization in pts with established CVD
- ⑩ Vascepa: Hypertriglyceridemia >500mg/dl

Lab results in past 30-60 days

Approvals typically good for 6-12 months

History of previous/current statin use

## Cost :

### ⑩ PCSK-9:

- Cash: 14,000/yr to \$5850
- Copay: \$500-\$1000 to \$50-\$200

### ⑩ Vascepa:

- Cash \$380
- Copay: \$25-380

# Sodium-glucose cotransporter 2 (SGLT2) Canaglifuzosin, Empagliflozin

University of California  
San Francisco

## Indication:

- ⑩ Diabetes Type 2 w/ or without HF

Prior use of metformin

Initial A1c >7.5

Previous meds tried

Trials: CANVAS, DECLARE-TIMI 58, EMPA-REG

Upcoming trials: EMPEROR HF, EMPEROR-PRESERVED, EMPERIAL, DELIVER, DAPA-HF

## Cost:

- ⑩ Cash: \$500
- ⑩ Copay: \$19-\$500

# Keys To Successful PAs

- ⑩ Access to prescription insurance cards
- ⑩ Thorough documentation by MD
- ⑩ Include primary literature in appeal letter
- ⑩ Smartphrases for documentation and communication
- ⑩ Follow up: delayed in-basket reminders